CERT:NASDAQ, Certara, Inc.
CERT stock overview
Certara, Inc. (CERT:NASDAQ) closed at $10.33 on October 23, 2026,
up 2.38% on the day.
The stock trades 20.2% below its 52-week high of $12.94
and 132.1% above its 52-week low of $4.45.
Over the past year, it lost 18.4%.
Certara, Inc. is part of the Health Care sector.
Key figures
- Price
- $10.33
- Day change
- +2.38%
- Volume
- 2,058,145
- Average volume
- 3,013,262
- Market cap
- 1B+
- 52-week range
- $4.45 – $12.94
- 50-day average
- $8.69
- 200-day average
- $7.22
Price action over the past year
In 252 trading sessions since October 23, 2025, CERT closed higher on 128 days (51%).
Its best day was June 16, 2026 (+16.12%) and its worst was November 7, 2025 (-23.07%).
The stock moved 10% or more in a single session 4 times.
Recent signals
CERT news
-
Oct 23, 2026:
Certara (CERT) Stock May Trade Above Fair Value On Its 75% Slump
-
Oct 11, 2026:
Certara (CERT) Stock Fair Value Edges Higher As Analysts Weigh Turnaround Progress
-
Oct 8, 2026:
What Could Go Wrong With Recursion Pharmaceuticals Stock?
-
Sep 30, 2026:
In-Silico Drug Discovery Market Report Now Available: Capitalize on AI-led R&D disruption as revenue surges from $3.3B to $6B by 2030; benchmark Certara, Insilico Medicine, Isomorphic Labs, Exscientia and BenevolentAI to secure share.
-
Sep 22, 2026:
Capitalize on Drug Discovery Informatics: Benchmark Schrödinger, Certara, Dotmatics, Thermo Fisher and BIOVIA to Accelerate R&D ROI and Secure Market Advantage
-
Sep 22, 2026:
Capitalize on Biosimulation's R&D Disruption: Benchmark Certara, Simulations Plus, Dassault Systèmes, Schrödinger and Applied BioMath to Accelerate Drug Pipelines and Secure ROI
-
Sep 14, 2026:
Certara (CERT) Slashes Jobs While Doubling Down On Software Growth
-
Sep 3, 2026:
Cerrado Gold Closes $10 Million Strategic Private Placement with Eric Sprott
About Certara, Inc.
Certara Inc accelerate medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trial, accelerate regulatory approval and increase patient access to medicines. The group has a business presence in the United States, EMEA and other regions, of which a majority of revenue is derived from the United States.
Similar stocks
Find more stocks like CERT with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.